Incorporating the Latest Therapeutic Strategies for HCC: Collaborating to Optimize Patient Outcomes
  • CME

Watch this CME-certified on-demand Webcast of a CCO symposium at AASLD 2019 to gain expert perspectives on the evolving treatment landscape for HCC, with a focus on first-line and second-line systemic therapy for advanced/unresectable disease.
Richard Finn, MD
Program Director
Anthony El-Khoueiry, MD
Josep M. Llovet, MD
Andrew X. Zhu, MD, PhD, FACP
Physicians: maximum of 1.75 AMA PRA Category 1 Credits
Released: January 7, 2020 Expiration: January 6, 2021

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Select optimal, individualized locoregional treatment for patients with HCC based on recent advances and evolving best practices to maximize clinical outcomes
  • Collaborate with the multidisciplinary team to integrate emerging targeted agents and immuno-oncology regimens for HCC into routine practice as clinically appropriate
  • Develop strategies to identify and mitigate unique adverse events associated with targeted agents and immunotherapy in patients with HCC
  • Refer appropriate patients with HCC to select ongoing clinical trials of novel agents and strategies

Information on this Educational Activity

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Program Director

Richard Finn, MD

Professor of Clinical Medicine
Division of Hematology-Oncology
Director, Signal Transduction and Therapeutics Program
Jonsson Comprehensive Cancer Center
David Geffen School of Medicine at UCLA
Los Angeles, California

Richard Finn, MD, has disclosed that he has received consulting fees from AstraZeneca, Bayer, Bristol-Myers Squibb, Eisai, Lilly, Merck, Novartis, Pfizer, and Roche/Genentech.


Anthony El-Khoueiry, MD

Associate Professor of Medicine
Division of Medical Oncology, Keck School of Medicine
Norris Comprehensive Cancer Center, University of Southern California
Los Angeles, California

Anthony El-Khoueiry, MD, has disclosed that he has received funds for research support from AstraZeneca, Astex, and Merck and consulting fees from Agenus, Bayer, Bristol-Myers Squibb, Eisai, and Merck.
Josep M. Llovet, MD

Professor of Medicine
Mount Sinai Liver Cancer Program
Division of Liver Diseases
Mount Sinai School of Medicine
Professor of Research
Liver Unit, IDIBAPS
Hospital Clínic Barcelona
Barcelona, Spain

Josep M. Llovet, MD, has disclosed that he has received funds for research support from Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Eisai, and Ipsen and consulting fees from Bayer, Bristol-Myers Squibb, Can-Fite, Celsion, Eisai, Exelixis, Fortress, Glycotest, Ipsen, Leerink Swann, Lilly, Merck, Midatech, Navigant, Nucleix, and Spring Bank.
Andrew X. Zhu, MD, PhD, FACP

Attending Oncologist
Massachusetts General Hospital Cancer Center
Boston, Massachusetts
Director, Jiahui International Cancer Center
Shanghai, China

Andrew X. Zhu, MD, PhD, FACP, has disclosed that he has received consulting fees from Bayer, Bristol-Myers Squibb, Eisai, Exelixis, Lilly, Merck, and Roche/Genentech.


Ryan P. Topping, PhD

Scientific Director

Ryan P. Topping, PhD, has no relevant conflicts of interest to report.
Kiran D. Mir-Hudgeons, PhD

Manager, Editorial Operations

Kiran Mir-Hudgeons, PhD, has no relevant conflicts of interest to report.
Tanja Link, PhD

Editorial Contributor

Tanja Link has no relevant conflicts of interest to report.
Timothy A. Quill, PhD

Associate Director, Scientific Services

Timothy Quill, PhD, has no relevant conflicts of interest to report.
Kevin Obholz, PhD

Senior Director, Educational Strategy

Kevin Obholz, PhD, has no relevant conflicts of interest to report.
Jason Everly, PharmD

Director, Program Development and Educational Impact

Jason Everly, PharmD, has no relevant conflicts of interest to report.
June Wasserstrom

Director, CME Program Development

June Wasserstrom has no relevant conflicts of interest to report.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This program is intended for physicians and other healthcare providers who treat and manage patients with hepatocellular carcinoma.


The goal of this activity is to improve participants’ knowledge of and competence in integrating new agents into the multidisciplinary treatment of patients with hepatocellular carcinoma.


Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 1.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.75 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from January 07, 2020, through January 06, 2021:

1. Register online at
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Related Content

From Clinical Care Options (CCO), expert commentary by Dr Richard Finn on the use of atezolizumab plus bevacizumab for advanced HCC

Richard Finn, MD Released: September 15, 2020

Gain key clinical insights quickly with this short slideset from Clinical Care Options (CCO) on immunotherapy for HCC

person default Lipika Goyal Goyal, MD, MPhil Amit G. Singal, MD, MS Released: September 14, 2020

Downloadable slideset on established and emerging biomarkers critical to optimal use of targeted therapy and immunotherapy in NSCLC, from Clinical Care Options (CCO)

Matthew Gubens, MD, MS Released: September 11, 2020

Gain key expert insights fast with this short slideset from CCO on biomarkers critical to optimal use of targeted therapy and immunotherapy for NSCLC

Matthew Gubens, MD, MS Sanjay Mukhopadhyay, MD Released: September 11, 2020
Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley

Supported by educational grants from
Bayer HealthCare Pharmaceuticals Inc.
Bristol-Myers Squibb
Merck & Co., Inc.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.


More info

CCO’s educational programs are available completely free of charge on the,, and Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?